Vertex Pharma stock heads toward pivotal FDA decision

Published on 11/11/2026 at 16:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma stock faces a pivotal regulatory checkpoint as the company broadens its commercial portfolio. Revenue growth supported higher 2026 guidance.

Growth Meets A Key FDA Catalyst

Third-quarter revenue increased 12 percent year over year as Vertex expanded beyond cystic fibrosis.
Management lifted full-year revenue guidance while acquisition and commercialization costs weighed on reported earnings.
The FDA has set November 30 as the target action date for povetacicept in IgA nephropathy.

Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Vertex Pharmaceuticals reported stronger third-quarter sales on November 2 and raised its full-year revenue outlook. The company is now approaching a November 30 FDA decision that could add nephrology as a new commercial franchise. Vertex Pharmaceuticals said total revenue rose 12 percent year over year to 3.44 billion US dollars in the quarter ended September 30.

Revenue Growth Broadens

Cystic fibrosis remained the largest contributor, with quarterly product revenue of 3.27 billion US dollars. Newer medicines also added to the mix, including Casgevy, Journavx and Palsonify following the closing of the Crinetics Pharmaceuticals acquisition.

GAAP net income fell to 653.6 million US dollars from 1.08 billion US dollars a year earlier, primarily because of expenses related to the Crinetics transaction. Non-GAAP net income was 1.21 billion US dollars, compared with 1.24 billion US dollars in the prior-year quarter.

Guidance Rises Ahead Of FDA Date

Vertex raised its 2026 total revenue guidance to 13.15 billion to 13.25 billion US dollars from 13.1 billion to 13.2 billion US dollars previously. The updated outlook includes at least 500 million US dollars in combined Casgevy and Journavx revenue and 40 million to 50 million US dollars from Palsonify.

The FDA is conducting a priority review of povetacicept for accelerated approval in IgA nephropathy. The application is supported by interim Phase 3 RAINIER results. If approved, the treatment would become Vertex's first commercialized therapy in nephrology. Management is also advancing the drug in primary membranous nephropathy and generalized myasthenia gravis.

Vertex Pharma Stock At Lang And Schwarz

Vertex Pharmaceuticals stock traded at 485.25 euros on Lang & Schwarz at 16:34 CET on Wednesday, November 11, 2026. The next clearly defined company-specific event is the FDA target action date on November 30, while investors will also assess whether newer products can offset the maturity of the cystic fibrosis franchise.